Financhill
Buy
61

ITCI Quote, Financials, Valuation and Earnings

Last price:
$126.47
Seasonality move :
2.93%
Day range:
$126.16 - $126.74
52-week range:
$62.78 - $128.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.73x
P/B ratio:
11.69x
Volume:
6M
Avg. volume:
3M
1-year change:
91.36%
Market cap:
$13.4B
Revenue:
$462.2M
EPS (TTM):
-$0.87

Analysts' Opinion

  • Consensus Rating
    Intra-Cellular Therapies has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
  • Price Target Downside
    According to analysts' consensus price target of $121.36, Intra-Cellular Therapies has an estimated downside of -3.83% from its current price of $126.20.
  • Price Target Upside
    According to analysts, the highest upside price target is $140.00 representing -- upside increase from its current price of $126.20.

Fair Value

  • According to the consensus of 11 analysts, Intra-Cellular Therapies has -3.83% downside to fair value with a price target of $121.36 per share.

ITCI vs. S&P 500

  • Over the past 5 trading days, Intra-Cellular Therapies has underperformed the S&P 500 by -2.83% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Intra-Cellular Therapies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Intra-Cellular Therapies has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Intra-Cellular Therapies reported revenues of $175.2M.

Earnings Growth

  • Intra-Cellular Therapies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Intra-Cellular Therapies reported earnings per share of -$0.25.
Enterprise value:
12.4B
EV / Invested capital:
--
Price / LTM sales:
20.73x
EV / EBIT:
--
EV / Revenue:
20.19x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-196.67x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$565.5M
Return On Assets:
-8.93%
Net Income Margin (TTM):
-14.1%
Return On Equity:
-10.58%
Return On Invested Capital:
-10.58%
Operating Margin:
-22.18%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $187.2M $418.1M $612.8M $125.8M $175.2M
Gross Profit $171M $388.3M $565.5M $116.7M $159.9M
Operating Income -$302.2M -$172.7M -$121.6M -$29.7M -$38.8M
EBITDA -$301.6M -$172.2M -$121.1M -$29.6M -$38.7M
Diluted EPS -$3.32 -$1.61 -$0.87 -$0.25 -$0.25
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $744.9M $533.2M $759.8M $702.4M $1.3B
Total Assets $771.3M $557M $782M $717.7M $1.3B
Current Liabilities $38M $49.9M $77.4M $103.1M $166.1M
Total Liabilities $61.9M $70.2M $96.6M $117M $179.6M
Total Equity $709.4M $486.8M $685.4M $600.7M $1.1B
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$304.2M -$161.3M -$62.2M -$25.3M -$26.5M
Cash From Investing -$127.1M $108.4M -$137.8M -$20.2M -$209.2M
Cash From Financing $460.9M $17M $564.9M $2.6M $6.7M
Free Cash Flow -$305M -$161.6M -$62.9M -$25.5M -$27.2M
ITCI
Sector
Market Cap
$13.4B
$44.7M
Price % of 52-Week High
--
51.72%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
91.36%
-33.41%
Beta (5-Year)
0.704
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $111.74
200-day SMA
Buy
Level $77.18
Bollinger Bands (100)
Buy
Level 70.86 - 94.24
Chaikin Money Flow
Sell
Level -403.7K
20-day SMA
Buy
Level $95.26
Relative Strength Index (RSI14)
Buy
Level 85.88
ADX Line
Buy
Level 48.43
Williams %R
Sell
Level -3.8156
50-day SMA
Buy
Level $89.75
MACD (12, 26)
Buy
Level 10.51
25-day Aroon Oscillator
Buy
Level 12
On Balance Volume
Neutral
Level 108.8M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (27.9599)
Buy
CA Score (Annual)
Level (0.3768)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (0.5989)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Stock Forecast FAQ

In the current month, ITCI has received 4 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ITCI average analyst price target in the past 3 months is $121.36.

  • Where Will Intra-Cellular Therapies Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Intra-Cellular Therapies share price will drop to $121.36 per share over the next 12 months.

  • What Do Analysts Say About Intra-Cellular Therapies?

    Analysts are divided on their view about Intra-Cellular Therapies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intra-Cellular Therapies is a Sell and believe this share price will rise from its current level to $87.00.

  • What Is Intra-Cellular Therapies's Price Target?

    The price target for Intra-Cellular Therapies over the next 1-year time period is forecast to be $121.36 according to 11 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.

  • Is ITCI A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Intra-Cellular Therapies is a Hold. 7 of 11 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of ITCI?

    You can purchase shares of Intra-Cellular Therapies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intra-Cellular Therapies shares.

  • What Is The Intra-Cellular Therapies Share Price Today?

    Intra-Cellular Therapies was last trading at $126.47 per share. This represents the most recent stock quote for Intra-Cellular Therapies. Yesterday, Intra-Cellular Therapies closed at $126.20 per share.

  • How To Buy Intra-Cellular Therapies Stock Online?

    In order to purchase Intra-Cellular Therapies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Sirius XM Be a 10-Bagger Stock?
Will Sirius XM Be a 10-Bagger Stock?

Last year, Warren Buffett surprised practically everyone when he acquired…

Will Quantum Computing Disrupt NVIDIA?
Will Quantum Computing Disrupt NVIDIA?

Earlier this month, NVIDIA CEO Jensen Huang seemingly dashed the…

What Trump Presidency Means For Stock Market
What Trump Presidency Means For Stock Market

Donald Trump was the first president in modern U.S. history…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Buy
59
NUKK alert for Jan 21

Nukkleus [NUKK] is up 7.25% over the past day.

Sell
45
QMCO alert for Jan 21

Quantum [QMCO] is up 14.36% over the past day.

Buy
51
QRVO alert for Jan 21

Qorvo [QRVO] is up 3.99% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock